EU/3/12/1068: Orphan designation for the treatment of African trypanosomiasis

Melarsoprol

Overview

On 8 November 2012, orphan designation (EU/3/12/1068) was granted by the European Commission to Pr. Peter Kennedy, United Kingdom, for melarsoprol for treatment of African trypanosomiasis.

The sponsorship was transferred to Stéphanie Gibaud, France, in February 2019.

Key facts

Active substance
Melarsoprol
Intended use
Treatment of African trypanosomiasis
Orphan designation status
Positive
EU designation number
EU/3/12/1068
Date of designation
08/11/2012
Sponsor

Stéphanie Gibaud
Université de Lorraine
Faculté de Pharmacie
7 avenue de la Fôret de Haye
BP 90170
54505 Vandœuvre-lès-Nancy
France
Tel. +33 6 68 47 41 00
E-mail: stephane.gibaud@univ-lorraine.fr

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating